A recently published study finds that cannabidiol (CBD), a non-psychoactive compound found in cannabis, can help reduce anxiety, hyperactivity and other symptoms associated with benzodiazepine withdrawal, a condition that remains difficult to treat and is considered a growing public health concern.
The research, published in Neuroscience Applied by scientists from Universidad Miguel Hernández, Dr. Balmis University Hospital and the Institute of Health Carlos III in Spain, examined whether CBD could reduce symptoms linked to withdrawal from alprazolam, a commonly prescribed benzodiazepine.
To test this, researchers developed an animal model of acute spontaneous alprazolam withdrawal using male and female mice. The animals were given gradually increasing doses of alprazolam over three weeks, followed by an abrupt cessation. Withdrawal symptoms were evaluated 24 hours later using standard behavioral tests that measure anxiety-like behavior, motor activity and physical withdrawal signs.
The results showed that alprazolam withdrawal triggered significant anxiety in both male and female mice, with particularly pronounced effects in females. Male mice also displayed increased hyperactivity, while both sexes showed physical changes such as more rearings and rubbings and fewer grooming behaviors. These findings align with known features of benzodiazepine withdrawal in humans, including heightened anxiety and agitation.
When researchers administered a single dose of CBD, many of these withdrawal-related effects were reduced. CBD significantly normalized anxiety-like behavior, reduced hyperactivity and improved somatic signs of withdrawal in both male and female mice.
Beyond behavior, the study also examined changes in brain regions linked to anxiety and stress, focusing on the amygdala and hippocampus. Alprazolam withdrawal altered the expression of genes involved in the GABAergic system, which is central to benzodiazepine action, as well as genes tied to the endocannabinoid system. CBD treatment largely reversed these changes, restoring several key markers toward baseline levels. It also normalized disruptions in circulating endocannabinoids caused by withdrawal.
Taken together, the findings suggest that CBD may counteract both the behavioral and biological disruptions associated with benzodiazepine withdrawal. While the authors emphasize that further research is needed, including human studies, they conclude that CBD warrants serious consideration as a potential new pharmacological option for managing alprazolam withdrawal.
More articles from The Marijuana Herald can be found below.
